Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

Andrea R Thurman, Jacques Ravel, Pawel Gajer, Mark A Marzinke, Louise A Ouattara, Terry Jacot, M Melissa Peet, Meredith R Clark, Gustavo F Doncel, Andrea R Thurman, Jacques Ravel, Pawel Gajer, Mark A Marzinke, Louise A Ouattara, Terry Jacot, M Melissa Peet, Meredith R Clark, Gustavo F Doncel

Abstract

Background: A relationship between the vaginal microbiota and tenofovir (TFV) concentrations and activity after topical administration has been previously reported.

Objective: CONRAD A15-138 was a randomized, placebo-controlled Phase I study aimed at characterizing the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TFV and levonorgestrel (LNG) administered through a vaginal ring (IVR) for 90 days. Herein, we describe changes from baseline in the vaginal microbiota with IVR use and the impact of the vaginal microbiota on mucosal TFV PK.

Methods: The study screened 68 participants and randomized 47 (37 TFV/LNG, 10 placebo), assessing the vaginal microbiota by sequencing the V3-V4 regions of 16S rRNA genes prior to IVR insertion and monthly for 3 months. Concentrations of TFV in vaginal fluid (VF), and TFV and TFV-diphosphate (TFV-DP) in vaginal tissue, and modeled PD against HIV-1 in vitro were measured before and after treatment.

Results: There were no clinically significant changes in relative abundance of vaginal bacterial phylotypes from pre-insertion baseline at any month among active and placebo IVR users. There were no significant changes in community state type (CST) with IVR use. Participants with diverse, anaerobic CST IVA/B microbiota had higher in vivo release of TFV from the IVR compared to women with Lactobacillus-dominated (LbD) microbiota, who had expected in vivo TFV release rates. Median VF TFV concentrations were significantly higher among women with CST IVA/B microbiota in months 1 (3,135 ng/mg VF) and 2 (3,800 ng/mg). Women with LbD microbiota had significantly higher median VF TFV concentration (1,423 ng/mg) and median TFV (103 ng/mg) and TFV-DP (5,877 fmol/mg) tissue concentrations versus women with CST IVA/B microbiota at month 3. All women demonstrated a significant increase from pre-insertion baseline of in vitro HIV-1 inhibition by VF (p values <0.05). PD differences in tissue according to CST, however, were not statistically significant.

Conclusion: TFV/LNG IVR use did not change the vaginal microbiota nor increase the incidence of CST IVA/B. Vaginal microbiota, and in particular CST IVA/B, possibly through increased vaginal pH, impacted in vivo TFV release and cervicovaginal (CV) PK, but both PK and PD data suggest CV protection against HIV-1.

Clinical trial registration: ClinicalTrials.gov (#NCT03279120).

Keywords: PrEP; multipurpose prevention technology; pre-exposure (PrEP) prophylaxis; tenofovir diphosphate; vaginal microbiome.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Thurman, Ravel, Gajer, Marzinke, Ouattara, Jacot, Peet, Clark and Doncel.

Figures

Figure 1
Figure 1
(A–C) Correlation of tenofovir (TFV) vaginal fluid concentration with the relative abundance of Gardnerella vaginalis at months 1, 2, and 3. Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis. Blue dots represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis.
Figure 2
Figure 2
(A–C) Correlation of tenofovir (TFV) vaginal fluid concentration with the relative abundance of Prevotella species at months 1, 2, and 3. Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Prevotella species. Blue dots represent participants who had diverse anaerobe dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Prevotella species.
Figure 3
Figure 3
(A–D) Correlation of TFV (A) and TFV-DP (C) tissue concentrations with relative abundance of G. vaginalis species and fit of the linear model with CST IV samples at the end of treatment with TFV tissue concentrations (B) and TFV-DP tissue concentrations (D). Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis. Blue dots represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis. Black dots in the linear fit model represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis.
Figure 4
Figure 4
Percent inhibition of HIV in vitro by cervicovaginal fluid lavage (CVL) supernatant obtained from study participants using the TFV/LNG IVR at baseline (BL) pre-insertion, month 1 (M1), and end of treatment month 3 (M3). Red dots represent participant data from individuals with diverse anaerobic CST IVA/B microbiota at sampling. Blue dots represent participant data from individuals with Lactobacillus-dominated (LbD) microbiota at sampling. p values < 0.01 paired change from BL in percent HIV inhibition at months 1 and months 3 for both LbD and CST IVA/B groups.
Figure 5
Figure 5
Cumulative (CUMU) p24 antigen production from cervicovaginal (CV) tissue biopsies obtained from all participants at baseline and from participants using the placebo IVR (BL). CUMU p24 antigen production from CV tissue biopsies obtained from participants using the TFV/LNG IVR at end of treatment (EOT). Red dots represent participant data from individuals with diverse anaerobic CST IVA/B microbiota at sampling. Blue dots represent participant data from individuals with Lactobacillus-dominated (LbD) microbiota at sampling. p values > 0.05 for change in p24 antigen production from tissues at EOT compared to BL.

References

    1. Abdool Karim S. S., Abdool Karim Q., Kharsany A. B., Baxter C., Grobler A. C., Werner L., et al. . (2015). Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl. J. Med. 373 (6), 530–539. doi: 10.1056/NEJMoa1410649
    1. Achilles S. L., Austin M. N., Meyn L. A., Mhlanga F., Chirenje Z. M., Hillier S. L. (2018). Impact of Contraceptive Initiation on Vaginal Microbiota. Am. J. Obstet. Gynecol. 218 (6), 622.e1–62.e10. doi: 10.1016/j.ajog.2018.02.017
    1. Amsel R., Totten P. A., Spiegel C. A., Chen K. C., Eschenbach D., Holmes K. K. (1983). Nonspecific Vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 74 (1), 14–22. doi: 10.1016/0002-9343(83)91112-9
    1. Atashili J., Poole C., Ndumbe P. M., Adimora A. A., Smith J. S. (2008). Bacterial Vaginosis and HIV Acquisition: A Meta-Analysis of Published Studies. AIDS 22 (12), 1493–1501. doi: 10.1097/QAD.0b013e3283021a37
    1. Balkus J. E., Richardson B. A., Rabe L. K., Taha T. E., Mgodi N., Kasaro M. P., et al. . (2014). Bacterial Vaginosis and the Risk of Trichomonas Vaginalis Acquisition Among HIV-1-Negative Women. Sex Transm. Dis. 41 (2), 123–128. doi: 10.1097/OLQ.0000000000000075
    1. Beer B. E., Doncel G. F., Krebs F. C., Shattock R. J., Fletcher P. S., Buckheit R. W., Jr., et al. . (2006). In Vitro Preclinical Testing of Nonoxynol-9 as Potential Anti-Human Immunodeficiency Virus Microbicide: A Retrospective Analysis of Results From Five Laboratories. Antimicrob. Agents Chemother. 50 (2), 713–723. doi: 10.1128/AAC.50.2.713-723.2006
    1. Brooks J. P., Edwards D. J., Blithe D. L., Fettweis J. M., Serrano M. G., Sheth N. U., et al. . (2017). Effects of Combined Oral Contraceptives, Depot Medroxyprogesterone Acetate and the Levonorgestrel-Releasing Intrauterine System on the Vaginal Microbiome. Contraception 95 (4), 405–413. doi: 10.1016/j.contraception.2016.11.006
    1. Brotman R. M., Bradford L. L., Conrad M., Gajer P., Ault K., Peralta L., et al. . (2012). Association Between Trichomonas Vaginalis and Vaginal Bacterial Community Composition Among Reproductive-Age Women. Sex Transm. Dis. 39 (10), 807–812. doi: 10.1097/OLQ.0b013e3182631c79
    1. Bushman L. R., Kiser J. J., Rower J. E., Klein B., Zheng J. H., Ray M. L., et al. . (2011). Determination of Nucleoside Analog Mono-, Di-, and Tri-Phosphates in Cellular Matrix by Solid Phase Extraction and Ultra-Sensitive LC-MS/MS Detection. J. Pharm. BioMed. Anal. 56 (2), 390–401. doi: 10.1016/j.jpba.2011.05.039
    1. Callahan B. J., McMurdie P. J., Rosen M. J., Han A. W., Johnson A. J., Holmes S. P. (2016). DADA2: High-Resolution Sample Inference From Illumina Amplicon Data. Nat. Methods 13 (7), 581–583. doi: 10.1038/nmeth.3869
    1. Cherpes T. L., Meyn L. A., Krohn M. A., Lurie J. G., Hillier S. L. (2003). Association Between Acquisition of Herpes Simplex Virus Type 2 in Women and Bacterial Vaginosis. Clin. Infect. Dis. 37 (3), 319–325. doi: 10.1086/375819
    1. Clark J. T., Clark M. R., Shelke N. B., Johnson T. J., Smith E. M., Andreasen A. K., et al. . (2014). Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy. PloS One 9 (3), e88509. doi: 10.1371/journal.pone.0088509
    1. Cohen R., Sheeder J., Teal S. B. (2019). Predictors of Discontinuation of Long-Acting Reversible Contraception Before 30 Months of Use by Adolescents and Young Women. J. Adolesc. Health 65 (2), 295–302. doi: 10.1016/j.jadohealth.2019.02.020
    1. Promega Corporation . (2021. a). Luminescent Cell Viability Assay Technical Bulletin, Tb2882015.
    1. Promega Corporation . (2021. b). Bright-Glo Luciferase Assay System Technical Manual, Tm0522015.
    1. Cottrell M. L., Kashuba A. D. (2014). Topical Microbicides and HIV Prevention in the Female Genital Tract. J. Clin. Pharmacol. 54 (6), 603–615. doi: 10.1002/jcph.292
    1. Crucitti T., Hardy L., van de Wijgert J., Agaba S., Buyze J., Kestelyn E., et al. . (2018). Contraceptive Rings Promote Vaginal Lactobacilli in a High Bacterial Vaginosis Prevalence Population: A Randomised, Open-Label Longitudinal Study in Rwandan Women. PloS One 13 (7), e0201003. doi: 10.1371/journal.pone.0201003
    1. Dabee S., Mugo N., Mudhune V., McLellan-Lemal E., Peacock S., O'Connor S., et al. . (2020). No Substantial Change in the Genital Microbiota Among Women Using a 90 Day Tenofofvir or Tenofovir/Levonorgestrel Intravaginal Ring in a Placebo Controlled Randomized Safety Trial in Kenya. HIV R4P 2020 (Cape Town South Africa (Virtual: ). Available at:
    1. Davies G. C., Feng L. X., Newton J. R., Dieben T. O., Coelingh-Bennink H. J. (1992). The Effects of a Combined Contraceptive Vaginal Ring Releasing Ethinyloestradiol and 3-Ketodesogestrel on Vaginal Flora. Contraception 45 (5), 511–518. doi: 10.1016/0010-7824(92)90163-N
    1. De Seta F., Restaino S., De Santo D., Stabile G., Banco R., Busetti M., et al. . (2012). Effects of Hormonal Contraception on Vaginal Flora. Contraception 86 (5), 526–529. doi: 10.1016/j.contraception.2012.02.012
    1. Dobard C., Sharma S., Martin A., Pau C. P., Holder A., Kuklenyik Z., et al. . (2011). Durable Protection From Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and its Relationship to Drug Levels in Tissue. J. Virol. 86 (2), 718–725. doi: 10.1128/JVI.05842-11
    1. El-Sahn M., Lucas J., Aikenhead M., Nemade R., Van Damme L. (2018). Understanding the Potential for Multipurpose Prevention of Pregnancy and HIV: Results From Surveys Assessing Four Hypothetical Concept Profiles of Multipurpose Prevention Technologies (MPTs) in Uganda, Nigeria and South Africa. Available at: .
    1. FDA (2018) Guidance for Industry Bioanalytical Method Validation Guidance for Industry Bioanalytical Method Validation. Available at: .
    1. France M. T., Ma B., Gajer P., Brown S., Humphrys M. S., Holm J. B., et al. . (2020). VALENCIA: A Nearest Centroid Classification Method for Vaginal Microbial Communities Based on Composition. Microbiome 8 (1), 166. doi: 10.1186/s40168-020-00934-6
    1. Gallo M. F., Macaluso M., Warner L., Fleenor M. E., Hook E. W., 3rd, Brill I., et al. . (2012). Bacterial Vaginosis, Gonorrhea, and Chlamydial Infection Among Women Attending a Sexually Transmitted Disease Clinic: A Longitudinal Analysis of Possible Causal Links. Ann. Epidemiol. 22 (3), 213–220. doi: 10.1016/j.annepidem.2011.11.005
    1. Hemalatha R., Ramalaxmi B. A., Swetha E., Balakrishna N., Mastromarino P. (2013). Evaluation of Vaginal pH for Detection of Bacterial Vaginosis. Indian J. Med. Res. 138 (3), 354–359.
    1. Hendrix C. W., Andrade A., Bumpus N. N., Kashuba A. D., Marzinke M. A., Moore A., et al. . (2016). Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res. Hum. Retroviruses 32 (1), 32–43. doi: 10.1089/aid.2015.0182
    1. Hillier S., Meyn L., Bunge K., Austin M., Moncla B., Dezzuitti C. S., et al. . (2017). “Impact of Vaginal Microbiota on Genital Tissue and Plasma Concentrations of Tenofovir,” in CROI, vol. 2017. (Seattle, WA, USA: ).
    1. Hoffman M. K., Bellad M. B., Charantimath U. S., Kavi A., Nagmoti J. M., Nagmoti M. B., et al. . (2017). A Comparison of Colorimetric Assessment of Vaginal pH With Nugent Score for the Detection of Bacterial Vaginosis. Infect. Dis. Obstet. Gynecol. 2017, 1040984. doi: 10.1155/2017/1040984
    1. Holm J. B., France M. T., Ma B., McComb E., Robinson C. K., Mehta A., et al. . (2020). Comparative Metagenome-Assembled Genome Analysis of "Candidatus Lachnocurva Vaginae", Formerly Known as Bacterial Vaginosis-Associated Bacterium-1 (Bvab1). Front. Cell Infect. Microbiol. 10, 117. doi: 10.3389/fcimb.2020.00117
    1. Holm J. B., Humphrys M. S., Robinson C. K., Settles M. L., Ott S., Fu L., et al. . (2019). Ultrahigh-Throughput Multiplexing and Sequencing of >500-Base-Pair Amplicon Regions on the Illumina HiSeq 2500 Platform. mSystems 4 (1), e00029–19. doi: 10.1128/mSystems.00029-19
    1. Huang Y., Merkatz R. B., Hillier S. L., Roberts K., Blithe D. L., Sitruk-Ware R., et al. . (2015). Effects of a One Year Reusable Contraceptive Vaginal Ring on Vaginal Microflora and the Risk of Vaginal Infection: An Open-Label Prospective Evaluation. PloS One 10 (8), e0134460. doi: 10.1371/journal.pone.0134460
    1. Johnson T. J., Clark M. R., Albright T. H., Nebeker J. S., Tuitupou A. L., Clark J. T., et al. . (2012). A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis. Antimicrob. Agents Chemother. 56 (12), 6272–6283. doi: 10.1128/AAC.01431-12
    1. Johnson L. F., Coetzee D. J., Dorrington R. E. (2005). Sentinel Surveillance of Sexually Transmitted Infections in South Africa: A Review. Sex Transm. Infect. 81 (4), 287–293. doi: 10.1136/sti.2004.013904
    1. Karim S. S., Kashuba A. D., Werner L., Karim Q. A. (2011). Drug Concentrations After Topical and Oral Antiretroviral Pre-Exposure Prophylaxis: Implications for HIV Prevention in Women. Lancet 378 (9787), 279–281. doi: 10.1016/S0140-6736(11)60878-7
    1. Kashuba A. D., Gengiah T. N., Werner L., Yang K. H., White N. R., Karim Q. A., et al. . (2015). Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. J. Acquir. Immune Defic. Syndr. 69 (3), 264–269. doi: 10.1097/QAI.0000000000000607
    1. Kenyon C., Colebunders R., Crucitti T. (2013). The Global Epidemiology of Bacterial Vaginosis: A Systematic Review. Am. J. Obstet. Gynecol. 209 (6), 505–523. doi: 10.1016/j.ajog.2013.05.006
    1. Kestelyn E., Agaba S., Van Nuil J. I., Uwineza M., Umulisa M. M., Mwambarangwe L., et al. . (2018). A Randomised Trial of a Contraceptive Vaginal Ring in Women at Risk of HIV Infection in Rwanda: Safety of Intermittent and Continuous Use. PloS One 13 (6), e0197572. doi: 10.1371/journal.pone.0197572
    1. Klatt N. R., Cheu R., Birse K., Zevin A. S., Perner M., Noel-Romas L., et al. . (2017). Vaginal Bacteria Modify HIV Tenofovir Microbicide Efficacy in African Women. Science 356 (6341), 938–945. doi: 10.1126/science.aai9383
    1. Koumans E. H., Sternberg M., Bruce C., McQuillan G., Kendrick J., Sutton M., et al. . (2007). The Prevalence of Bacterial Vaginosis in the United States, 2001-2004; Associations With Symptoms, Sexual Behaviors, and Reproductive Health. Sex Transm. Dis. 34 (11), 864–869. doi: 10.1097/OLQ.0b013e318074e565
    1. Kuczynski J., Stombaugh J., Walters W. A., Gonzalez A., Caporaso J. G., Knight R. (2012). Using QIIME to Analyze 16S rRNA Gene Sequences From Microbial Communities. Curr. Protoc. Microbiol. Chapter 1, Unit 1E 5. doi: 10.1002/9780471729259.mc01e05s27
    1. McKinnon L. R., Achilles S. L., Bradshaw C. S., Burgener A., Crucitti T., Fredricks D. N., et al. . (2019). The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. AIDS Res. Hum. Retroviruses 35 (3), 219–228. doi: 10.1089/aid.2018.0304
    1. Mitra A., MacIntyre D. A., Marchesi J. R., Lee Y. S., Bennett P. R., Kyrgiou M. (2016). The Vaginal Microbiota, Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia: What do We Know and Where are We Going Next? Microbiome 4 (1), 58. doi: 10.1186/s40168-016-0203-0
    1. Mugo N., Mudhune V., Heffron R., Thomas K. T., McLellan-Lemal E., Peacock S., et al. . (2021). “Randomized, Placebo-Controlled Trial of Safety, Pharmacokinetics, and Pharmacodynamics of 90-Day Intravaginal Rings (IVRs) Releasing Tenofovir (TFV) With and Without Levonorgestrel (LNG) Among Women in Western Kenya”, in HIV R4P Virtual Conference. Available at: . Oral Presentation.
    1. Myer L., Denny L., Telerant R., Souza M., Wright T. C., Jr., Kuhn L. (2005). Bacterial Vaginosis and Susceptibility to HIV Infection in South African Women: A Nested Case-Control Study. J. Infect. Dis. 192 (8), 1372–1380. doi: 10.1086/462427
    1. Nugent R. P., Krohn M. A., Hillier S. L. (1991). Reliability of Diagnosing Bacterial Vaginosis is Improved by a Standardized Method of Gram Stain Interpretation. J. Clin. Microbiol. 29 (2), 297–301. doi: 10.1128/jcm.29.2.297-301.1991
    1. Ouattara L. A., Thurman A. R., Jacot T. A., Cottrell M., Sykes C., Blake K., et al. . (2022. a). Genital Mucosal Drug Concentrations and Anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral. Admin. J. Acquir. Immune Defic. Syndr. 89 (1), 87–97. doi: 10.1097/QAI.0000000000002820
    1. Ouattara L. A., Vann N. C., Doncel G. F. (2022. b). Ex Vivo HIV Infection Model of Cervico-Vaginal and Rectal Tissue. Methods Mol. Biol. 2407, 157–172. doi: 10.1007/978-1-0716-1871-4_12
    1. Parikh U. M., Dobard C., Sharma S., Cong M. E., Jia H., Martin A., et al. . (2009). Complete Protection From Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or With Emtricitabine. J. Virol. 83 (20), 10358–10365. doi: 10.1128/JVI.01073-09
    1. Pillay D., Chersich M., Morroni C., Pleaner M., Adeagbo O. A., Naidoo N., et al. . (2017). User Perspectives on Implanon NXT in South Africa: A Survey of 12 Public-Sector Facilities. S Afr Med. J. 107 (10), 815–821. doi: 10.7196/SAMJ.2017.v107i10.12833
    1. Ravel J., Gajer P., Abdo Z., Schneider G. M., Koenig S. S., McCulle S. L., et al. . (2012). Vaginal Microbiome of Reproductive-Age Women. Proc. Natl. Acad. Sci. U.S.A. 108 Suppl 1, 4680–4687. doi: 10.1073/pnas.1002611107
    1. Richardson-Harman N., Lackman-Smith C., Fletcher P. S., Anton P. A., Bremer J. W., Dezzutti C. S., et al. . (2009). Multisite Comparison of Anti-Human Immunodeficiency Virus Microbicide Activity in Explant Assays Using a Novel Endpoint Analysis. J. Clin. Microbiol. 47 (11), 3530–3539. doi: 10.1128/JCM.00673-09
    1. Richardson-Harman N., Mauck C., McGowan I., Anton P. (2012). Dose-Response Relationship Between Tissue Concentrations of UC781 and Explant Infectibility With HIV Type 1 in the RMP-01 Rectal Safety Study. AIDS Res. Hum. Retroviruses 28 (11), 1422–1433. doi: 10.1089/aid.2012.0073
    1. Rosen G. H., Randis T. M., Desai P. V., Sapra K. J., Ma B., Gajer P., et al. . (2017). Group B Streptococcus and the Vaginal Microbiota. J. Infect. Dis. 216 (6), 744–751. doi: 10.1093/infdis/jix395
    1. Roumen F. J., Boon M. E., van Velzen D., Dieben T. O., Coelingh Bennink H. J. (1996). The Cervico-Vaginal Epithelium During 20 Cycles' Use of a Combined Contraceptive Vaginal Ring. Hum. Reprod. 11 (11), 2443–2448. doi: 10.1093/oxfordjournals.humrep.a019134
    1. Roxby A. C., Fredricks D. N., Odem-Davis K., Asbjornsdottir K., Masese L., Fiedler T. L., et al. . (2016). Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. J. Acquir. Immune Defic. Syndr. 71 (4), 359–366. doi: 10.1097/QAI.0000000000000866
    1. Roy S., Wilkins J., Mishell D. R., Jr. (1981). The Effect of a Contraceptive Vaginal Ring and Oral Contraceptives on the Vaginal Flora. Contraception 24 (4), 481–491. doi: 10.1016/0010-7824(81)90011-1
    1. Sanu O., Lamont R. F. (2011). Periodontal Disease and Bacterial Vaginosis as Genetic and Environmental Markers for the Risk of Spontaneous Preterm Labor and Preterm Birth. J. Matern. Fetal Neonatal Med. 24 (12), 1476–1485. doi: 10.3109/14767058.2010.545930
    1. Schmieder R., Lim Y. W., Rohwer F., Edwards R. (2010). TagCleaner: Identification and Removal of Tag Sequences From Genomic and Metagenomic Datasets. BMC Bioinf. 11, 341. doi: 10.1186/1471-2105-11-341
    1. Shieh E., Marzinke M. A., Fuchs E. J., Hamlin A., Bakshi R., Aung W., et al. . (2019). Transgender Women on Oral HIV Pre-Exposure Prophylaxis Have Significantly Lower Tenofovir and Emtricitabine Concentrations When Also Taking Oestrogen When Compared to Cisgender Men. J. Int. AIDS Soc. 22 (11), e25405. doi: 10.1002/jia2.25405
    1. Sznajder K. K., Tomaszewski K. S., Burke A. E., Trent M. (2017). Incidence of Discontinuation of Long-Acting Reversible Contraception Among Adolescent and Young Adult Women Served by an Urban Primary Care Clinic. J. Pediatr. Adolesc. Gynecol. 30 (1), 53–57. doi: 10.1016/j.jpag.2016.06.012
    1. Taha T. E., Hoover D. R., Dallabetta G. A., Kumwenda N. I., Mtimavalye L. A., Yang L. P., et al. . (1998). Bacterial Vaginosis and Disturbances of Vaginal Flora: Association With Increased Acquisition of HIV. AIDS 12 (13), 1699–1706. doi: 10.1097/00002030-199813000-00019
    1. Taneva E., Sinclair S., Mesquita P. M., Weinrick B., Cameron S. A., Cheshenko N., et al. . (2018). Vaginal Microbiome Modulates Topical Antiretroviral Drug Pharmacokinetics. JCI Insight 3 (13), e99545. doi: 10.1172/jci.insight.99545
    1. Teunissen A. M., Grimm B., Roumen F. J. (2014). Continuation Rates of the Subdermal Contraceptive Implanon((R)) and Associated Influencing Factors. Eur. J. Contracept Reprod. Health Care 19 (1), 15–21. doi: 10.3109/13625187.2013.862231
    1. Thurman A., Brache V., Ouattara A., Chandra N., Jacot T., Jackson S., et al. . (2021). Randomized, Placebo Controlled Phase I Trial of Safety, Pharmacokinetics, Pharmacodynamics and Acceptability of a Multipurpose Prevention Vaginal Ring Containing Tenofovir and Levonorgestrel HIV R4P (Virtual, Cape Town, South Africa: ). Available at: .
    1. Thurman A. R., Doncel G. F. (2011). Innate Immunity and Inflammatory Response to Trichomonas Vaginalis and Bacterial Vaginosis: Relationship to HIV Acquisition. Am. J. Reprod. Immunol. 65 (2), 89–98. doi: 10.1111/j.1600-0897.2010.00902.x
    1. Thurman A. R., Schwartz J. L., Brache V., Clark M. R., McCormick T., Chandra N., et al. . (2018). Randomized, Placebo Controlled Phase I Trial of Safety, Pharmacokinetics, Pharmacodynamics and Acceptability of Tenofovir and Tenofovir Plus Levonorgestrel Vaginal Rings in Women. PloS One 13 (6), e0199778. doi: 10.1371/journal.pone.0199778
    1. Thurman A. R., Schwartz J. L., Ravel J., Gajer P., Marzinke M. A., Yousefieh N., et al. . (2019). Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using Tenofovir and Tenofovir/Levonorgestrel Vaginal Rings. PloS One 14 (5), e0217229. doi: 10.1371/journal.pone.0217229
    1. Veres S., Miller L., Burington B. (2004). A Comparison Between the Vaginal Ring and Oral Contraceptives. Obstet. Gynecol. 104 (3), 555–563. doi: 10.1097/01.AOG.0000136082.59644.13
    1. Wei X., Decker J. M., Liu H., Zhang Z., Arani R. B., Kilby J. M., et al. . (2002). Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. Antimicrob. Agents Chemother. 46 (6), 1896–1905. doi: 10.1128/AAC.46.6.1896-1905.2002
    1. Wiesenfeld H. C., Hillier S. L., Krohn M. A., Landers D. V., Sweet R. L. (2003). Bacterial Vaginosis is a Strong Predictor of Neisseria Gonorrhoeae and Chlamydia Trachomatis Infection. Clin. Infect. Dis. 36 (5), 663–668. doi: 10.1086/367658

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever